MSD ventures into fibroblast therapies with $1.9bn deal with Mestag
MSD (Merck & Co) has signed a license and collaboration agreement with Mestag Therapeutics to develop new fibroblast therapies for…
07 Oct 2024
ProductLife boosts drug development with IntiQuan acquisition
ProductLife Group (PLG) has announced the acquisition of IntiQuan, a Swiss firm specialising in pharmacometrics. The move enhances PLG's capabilities in drug development, focusing on reducing risk, costs and timelines…
07 Oct 2024
OnKure and Reneo Pharmaceuticals complete merger
OnKure has announced the successful completion of its merger with Reneo Pharmaceuticals, with the combined entity set to operate under the OnKure Therapeutics name. The shares will commence trading on…
30 Sep 2024
Valerio Therapeutics announces acquisition of Emglev Therapeutics
Valerio Therapeutics, a developer of DNA Decoy therapeutics, has announced its acquisition of Emglev Therapeutics, a company specialising in single-domain antibody-based therapeutics. This strategic move aims to enhance Valerio's drug…
17 Sep 2024
MaxCyte and Kamau Therapeutics sign platform license agreement
MaxCyte, a company specialising in cell engineering technologies, has entered a strategic platform licence (SPL) agreement with Kamau Therapeutics, a clinical-stage company focused on stem cell therapy gene correction, to…
27 Aug 2024
UCB to divest China neurology and allergy business for $680m
Biopharmaceutical company UCB has entered a divestment agreement in China to sell, divest and license its mature neurology and allergy business to CBC Group and Mubadala in a deal valued…
23 Aug 2024
Rafael Holdings and Cyclo Therapeutics enter merger deal
Rafael Holdings has signed a definitive merger agreement with Cyclo Therapeutics, aiming to enhance the development of Trappsol Cyclo, a treatment for Niemann-Pick disease type C1. The merger will result…